

# Francisco Cervantes Requena

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8456879/francisco-cervantes-requena-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

239  
papers

23,275  
citations

53  
h-index

152  
g-index

243  
ext. papers

25,916  
ext. citations

4.1  
avg, IF

5.99  
L-index

#	Paper	IF	Citations
239	Momelotinib reduces transfusion requirements in patients with myelofibrosis.. <i>Leukemia and Lymphoma</i> , <b>2022</b> , 1-5	1.9	0
238	A Randomized, Phase 3 Trial of Fedratinib Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Previously Treated with Ruxolitinib (FREEDOM2). <i>Blood</i> , <b>2021</b> , 138, 3643-3643	2.2	2
237	Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study. <i>Leukemia</i> , <b>2021</b> , 35, 3455-3465	10.7	10
236	Genomic characterization of patients with polycythemia vera developing resistance to hydroxyurea. <i>Leukemia</i> , <b>2021</b> , 35, 623-627	10.7	2
235	Next-generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 89-95	13.4	9
234	Reply to: Correspondence on "Next-generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis". <i>Journal of Hepatology</i> , <b>2021</b> , 74, 252-254	13.4	
233	The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia. <i>Leukemia</i> , <b>2020</b> , 34, 2138-2149	10.7	17
232	Natural history of polycythemia vera and essential thrombocythemia presenting with splanchnic vein thrombosis. <i>Annals of Hematology</i> , <b>2020</b> , 99, 791-798	3	7
231	Clinico-biological characteristics of patients with myelofibrosis: an analysis of 1,000 cases from the Spanish Registry of Myelofibrosis. <i>Medicina Clínica</i> , <b>2020</b> , 155, 152-158	1	2
230	Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases. <i>American Journal of Hematology</i> , <b>2020</b> , 95, 156-166	7.1	27
229	Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group. <i>American Journal of Hematology</i> , <b>2020</b> , 95, E1-E3	7.1	3
228	Clinico-biological characteristics of patients with myelofibrosis: an analysis of 1,000 cases from the Spanish Registry of Myelofibrosis. <i>Medicina Clínica (English Edition)</i> , <b>2020</b> , 155, 152-158	0.3	1
227	Predicting Survival after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: Performance of the Myelofibrosis Transplant Scoring System (MTSS) and Development of a New Prognostic Model. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 2237-2244	4.7	5
226	Safety and efficacy of the combination of sonidegib and ruxolitinib in myelofibrosis: a phase 1b/2 dose-finding study. <i>Blood Advances</i> , <b>2020</b> , 4, 3063-3071	7.8	3
225	Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients. <i>Cancer Medicine</i> , <b>2019</b> , 8, 4089-4092	4.8	10
224	Conventional and molecular cytogenetic studies to characterize 32 complex variant Philadelphia translocations in patients with chronic myeloid leukemia. <i>Oncology Letters</i> , <b>2019</b> , 17, 5705-5710	2.6	3
223	Genomic characterization in triple-negative primary myelofibrosis and other myeloid neoplasms with bone marrow fibrosis. <i>Annals of Hematology</i> , <b>2019</b> , 98, 2319-2328	3	3

222	Dynamic and Time-to-Event Analyses Demonstrate Marked Reduction in Transfusion Requirements for Janus Kinase Inhibitor-Naïve Myelofibrosis Patients Treated with Momelotinib Compared Head to Head with Ruxolitinib. <i>Blood</i> , <b>2019</b> , 134, 1663-1663	2.2	3
221	Baseline Mutational Status of Patients with Myelofibrosis and Anemia in the Realise Trial and Impact on Outcome. <i>Blood</i> , <b>2019</b> , 134, 2952-2952	2.2	
220	Impact of Bone Marrow Fibrosis Grade in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis. a Study of the Mysec Group. <i>Blood</i> , <b>2019</b> , 134, 2946-2946	2.2	
219	Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. <i>Leukemia</i> , <b>2018</b> , 32, 1057-1069	10.7	263
218	Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. <i>Haematologica</i> , <b>2018</b> , 103, e392-e394	6.6	20
217	Prognostic risk models for transplant decision-making in myelofibrosis. <i>Annals of Hematology</i> , <b>2018</b> , 97, 813-820	3	5
216	Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. <i>Lancet Haematology</i> , <b>2018</b> , 5, e73-e81	14.6	115
215	Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia. <i>Leukemia Research</i> , <b>2018</b> , 69, 100-102	2.7	5
214	Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms. <i>Blood Cancer Journal</i> , <b>2018</b> , 8, 25	7	18
213	Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia. <i>British Journal of Haematology</i> , <b>2018</b> , 181, 397-400	4.5	18
212	Detection of inflammatory monocytes but not mesenchymal stem/stromal cells in peripheral blood of patients with myelofibrosis. <i>British Journal of Haematology</i> , <b>2018</b> , 181, 133-137	4.5	5
211	Feasibility of Treatment Discontinuation in Chronic Myeloid Leukemia in Clinical Practice in Spain: Results from a Nationwide Series of 236 Patients. <i>Blood</i> , <b>2018</b> , 132, 47-47	2.2	1
210	Excess Mortality in Polycythemia Vera and Essential Thrombocythemia. <i>Blood</i> , <b>2018</b> , 132, 3042-3042	2.2	0
209	Pooled Analyses of Total Symptom Score (TSS) Responses in Patients with Myelofibrosis (MF) Treated with Pacritinib (PAC) Vs Best Available Therapy (BAT) in Phase 3 Studies (PERSIST-1, PERSIST-2). <i>Blood</i> , <b>2018</b> , 132, 4281-4281	2.2	
208	Triple Negative Myelofibrosis and Myelodysplastic Syndrome with Fibrosis: Clinico-Biological Characterization and Correlation with Gene Mutations. <i>Blood</i> , <b>2018</b> , 132, 4299-4299	2.2	
207	Solid Tumors in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis: A Study on 2220 Patients. <i>Blood</i> , <b>2018</b> , 132, 3039-3039	2.2	
206	Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients. <i>Blood Cancer Journal</i> , <b>2018</b> , 8, 91	7	24
205	Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project. <i>Blood Cancer Journal</i> , <b>2018</b> , 8, 89	7	8

204	Evaluation of resistance to HIV-1 infection ex vivo of PBMCs isolated from patients with chronic myeloid leukemia treated with different tyrosine kinase inhibitors. <i>Biochemical Pharmacology</i> , <b>2018</b> , 156, 248-264	6	10
203	Essential thrombocythaemia with mutation in : clinicopathological correlation and comparison with 2V617F-mutated and mutated genotypes. <i>Journal of Clinical Pathology</i> , <b>2018</b> , 71, 975-980	3.9	9
202	No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2017</b> , 143, 843-850	4.9	26
201	Selective testing for calreticulin gene mutations in patients with splanchnic vein thrombosis: A prospective cohort study. <i>Journal of Hepatology</i> , <b>2017</b> , 67, 501-507	13.4	37
200	Impact of genotype on leukaemic transformation in polycythaemia vera and essential thrombocythaemia. <i>British Journal of Haematology</i> , <b>2017</b> , 178, 764-771	4.5	19
199	Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group. <i>Haematologica</i> , <b>2017</b> , 102, 85-93	6.6	29
198	Socioeconomic burden of participation in clinical trials in patients with myeloproliferative neoplasms. <i>European Journal of Haematology</i> , <b>2017</b> , 99, 36-41	3.8	2
197	Predictive factors for anemia response to erythropoiesis-stimulating agents in myelofibrosis. <i>European Journal of Haematology</i> , <b>2017</b> , 98, 407-414	3.8	13
196	Does ruxolitinib prolong the survival of patients with myelofibrosis?. <i>Blood</i> , <b>2017</b> , 129, 832-837	2.2	70
195	Ponatinib in chronic myeloid leukemia (CML): Consensus on patient treatment and management from a European expert panel. <i>Critical Reviews in Oncology/Hematology</i> , <b>2017</b> , 120, 52-59	7	27
194	Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. <i>Journal of Hematology and Oncology</i> , <b>2017</b> , 10, 156	22.4	137
193	SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3844-3850	2.2	139
192	Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs. <i>Leukemia Research</i> , <b>2017</b> , 63, 34-40	2.7	12
191	Imatinib dose reduction in patients with chronic myeloid leukemia in sustained deep molecular response. <i>Annals of Hematology</i> , <b>2017</b> , 96, 81-85	3	15
190	Phase 3 trial of momelotinib (MMB) vs ruxolitinib (RUX) in JAK inhibitor (JAKi) naive patients with myelofibrosis (MF).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 7000-7000	2.2	4
189	Phase 3 randomized trial of momelotinib (MMB) versus best available therapy (BAT) in patients with myelofibrosis (MF) previously treated with ruxolitinib (RUX).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 7001-7001	2.2	14
188	Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation. <i>Haematologica</i> , <b>2016</b> , 101, 926-31	6.6	91
187	Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 151-9	2.2	42

186	Alleviating anemia and thrombocytopenia in myelofibrosis patients. <i>Expert Review of Hematology</i> , <b>2016</b> , 9, 489-96	2.8	8
185	Long-term results of prednisone treatment for the anemia of myelofibrosis. <i>Leukemia and Lymphoma</i> , <b>2016</b> , 57, 120-4	1.9	12
184	A Pooled Overall Survival (OS) Analysis of 5-Year Data from the COMFORT-I and COMFORT-II Trials of Ruxolitinib for the Treatment of Myelofibrosis (MF). <i>Blood</i> , <b>2016</b> , 128, 3110-3110	2.2	7
183	Symptom Burden As Primary Driver for Therapy in Patients with Myelofibrosis: An Analysis By MPN International Quality of Life Study Group. <i>Blood</i> , <b>2016</b> , 128, 3117-3117	2.2	4
182	Clinical Outcomes with Ruxolitinib (RUX) in Patients with Myelofibrosis (MF) Stratified By Transfusion Status: A Pooled Analysis of the COMFORT-I and -II Trials. <i>Blood</i> , <b>2016</b> , 128, 3118-3118	2.2	1
181	Pacritinib (PAC) vs best available therapy (BAT) in myelofibrosis (MF): Long-term follow-up of patient-reported outcomes (PROs) in the phase III PERSIST-1 trial.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 7067-7067	2.2	1
180	The telomerase inhibitor imetelstat in patients (pts) with intermediate-2 or high-risk myelofibrosis (MF) previously treated with Janus kinase (JAK) inhibitor: A phase 2, randomized study.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, TPS7079-TPS7079	2.2	
179	Consideration of Symptom Burden Based Treatment in PV and ET Patients: An Analysis By MPN International Quality of Life Study Group. <i>Blood</i> , <b>2016</b> , 128, 5463-5463	2.2	
178	The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group. <i>Cancer</i> , <b>2016</b> , 122, 1888-96	6.4	11
177	Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results. <i>Annals of Hematology</i> , <b>2015</b> , 94, 1791-6	3	37
176	Novel therapies for myelofibrosis. <i>Leukemia and Lymphoma</i> , <b>2015</b> , 56, 2768-78	1.9	7
175	BCL2 gene polymorphisms and splicing variants in chronic myeloid leukemia. <i>Leukemia Research</i> , <b>2015</b> , 39, 1278-1278	2.7	5
174	Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2015</b> , 1, 643-51	13.4	242
173	Role of calreticulin mutations in the aetiological diagnosis of splanchnic vein thrombosis. <i>Journal of Hepatology</i> , <b>2015</b> , 62, 72-4	13.4	59
172	Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis. <i>Blood</i> , <b>2015</b> , 125, 3347-50; quiz 3364	2.2	114
171	A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. <i>Haematologica</i> , <b>2015</b> , 100, 1139-45	6.6	151
170	A Study of the Role of Antiplatelet Therapy in the Prevention of Thrombosis in Patients with Calr-Mutated Low Risk Essential Thrombocythemia. <i>Blood</i> , <b>2015</b> , 126, 1602-1602	2.2	2
169	Treatment-Free Remission (TFR) Eligibility in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Residual Disease on Long-Term Imatinib (IM) Who Switched to Second-Line Nilotinib (NIL). <i>Blood</i> , <b>2015</b> , 126, 4029-4029	2.2	3

168	Impact of Disease Duration upon Symptom Burden Amongst Patients with Myeloproliferative Neoplasms (MPNs). <i>Blood</i> , <b>2015</b> , 126, 4073-4073	2.2	2
167	Symptom Burden Profile in Myelofibrosis Patients with Thrombocytopenia: Lessons and Unmet Needs. <i>Blood</i> , <b>2015</b> , 126, 4080-4080	2.2	3
166	Analysis of Outcomes By Patient Subgroups in Patients with Myelofibrosis Treated with Pacritinib Vs Best Available Therapy (BAT) in the Phase III Persist-1 Trial. <i>Blood</i> , <b>2015</b> , 126, 58-58	2.2	2
165	Long-Term Efficacy and Safety in COMFORT-II, a Phase 3 Study Comparing Ruxolitinib with Best Available Therapy for the Treatment of Myelofibrosis: 5-Year Final Study Results. <i>Blood</i> , <b>2015</b> , 126, 59-59 <sup>2,2</sup>	2.2	6
164	The EUTOS Survival Score Is Preferable over the Sokal Score for Prognosis of Long-Term Survival of Patients with Chronic Myeloid Leukemia. <i>Blood</i> , <b>2015</b> , 126, 595-595	2.2	3
163	Phase 1b/2 Study of the Efficacy and Safety of Sonidegib (LDE225) in Combination with Ruxolitinib (INC424) in Patients with Myelofibrosis. <i>Blood</i> , <b>2015</b> , 126, 825-825	2.2	22
162	What we can do about anemia in myelofibrosis <b>2015</b> , 124-135		
161	Unmet Needs for Symptom Control in Essential Thrombocythemia with Front Line Therapy. <i>Blood</i> , <b>2015</b> , 126, 5175-5175	2.2	
160	Relationship Between Patient-Reported Outcomes (PROs) and Health-Related Quality of Life (HRQoL) and Efficacy in Patients with Myelofibrosis in the Phase III Persist-1 Trial of Pacritinib Vs. Best Available Therapy (BAT). <i>Blood</i> , <b>2015</b> , 126, 1609-1609	2.2	
159	Use of the Functional Assessment of Cancer Therapy--anemia in persons with myeloproliferative neoplasm-associated myelofibrosis and anemia. <i>Clinical Therapeutics</i> , <b>2014</b> , 36, 560-6	3.5	14
158	Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. <i>Haematologica</i> , <b>2014</b> , 99, 292-8	6.6	35
157	Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients. <i>Blood</i> , <b>2014</b> , 123, 3803-10	2.2	65
156	Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib. <i>Blood</i> , <b>2014</b> , 124, 729-36	2.2	75
155	Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. <i>Blood</i> , <b>2014</b> , 123, 1833-5	2.2	86
154	How I treat myelofibrosis. <i>Blood</i> , <b>2014</b> , 124, 2635-42	2.2	111
153	Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. <i>Blood</i> , <b>2014</b> , 124, 1062-9	2.2	268
152	Indirect and non-medical economic burden, quality-of-life, and disabilities of the myelofibrosis disease in Spain. <i>Journal of Medical Economics</i> , <b>2014</b> , 17, 435-41	2.4	6
151	Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up. <i>American Journal of Hematology</i> , <b>2014</b> , 89, 732-42	7.1	83



150	Relationship between the 46/1 haplotype of the JAK2 gene and the JAK2 mutational status and allele burden, the initial findings, and the survival of patients with myelofibrosis. <i>Annals of Hematology</i> , <b>2014</b> , 93, 797-802	3	7
149	Survival and Prognosis in Patients with First-Line Imatinib Treatment Under Particular Consideration of Death Due to Chronic Myeloid Leukemia. <i>Blood</i> , <b>2014</b> , 124, 153-153	2.2	4
148	Post-Polycythemia and Post-Thrombocytopenia Myelofibrosis Have Distinctive Clinical Phenotypes: An International Multicenter Study on 718 Patients. <i>Blood</i> , <b>2014</b> , 124, 1824-1824	2.2	1
147	Symptom Severity and Clinical Variables of Polycythemia Vera Patients with Splenomegaly, Phlebotomy Requirements and/or Hydroxyurea Use: a Retrospective Evaluation of 1334 Patients. <i>Blood</i> , <b>2014</b> , 124, 1848-1848	2.2	2
146	Towards a Better Understanding of Epidemiology, Survival and Treatment in Myeloproliferative Neoplasms: Results of the European Leukemianet Registry (ERNEST study). <i>Blood</i> , <b>2014</b> , 124, 1849-1849 <sup>2.2</sup>	2.2	2
145	Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasms: A Study of the AGIMM & IWG-MRT Groups in 519 Subjects. <i>Blood</i> , <b>2014</b> , 124, 3163-3163	2.2	1
144	Mutation-Enhanced International Prognostic Scoring System (MIPSS) for Primary Myelofibrosis: An AGIMM & IWG-MRT Project. <i>Blood</i> , <b>2014</b> , 124, 405-405	2.2	39
143	Phase 1b Dose-Escalation Study of Sonidegib (LDE225) in Combination with Ruxolitinib (INC424) in Patients with Myelofibrosis. <i>Blood</i> , <b>2014</b> , 124, 712-712	2.2	7
142	Effect of continued imatinib (IM) in pts with detectable BCR-ABL after 12 years on study on deep molecular responses (MR): 36-month update from ENESTcmr.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 7025-7025	2.2	1
141	Survival of Allogeneic Stem Cell Transplantation Vs Conventional Therapies per DIPSS Stratification in Patients with Primary Myelofibrosis Younger Than 65 Years: A Retrospective Analysis on 673 Patients. <i>Blood</i> , <b>2014</b> , 124, 633-633	2.2	
140	Low Risk IPSS/DIPSS Primary Myelofibrosis: Identification of Patients with Higher Risk of Progression. <i>Blood</i> , <b>2014</b> , 124, 3187-3187	2.2	
139	Myelofibrosis: an update on current pharmacotherapy and future directions. <i>Expert Opinion on Pharmacotherapy</i> , <b>2013</b> , 14, 873-84	4	10
138	Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. <i>Blood</i> , <b>2013</b> , 122, 1395-8	2.2	218
137	Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. <i>Blood</i> , <b>2013</b> , 122, 4047-53	2.2	328
136	European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. <i>Blood</i> , <b>2013</b> , 122, 872-84	2.2	1413
135	The ERCC2 Gln/Gln polymorphism at codon 751 is not associated with leukaemic transformation in primary myelofibrosis. <i>British Journal of Haematology</i> , <b>2013</b> , 162, 424-7	4.5	4
134	Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. <i>British Journal of Haematology</i> , <b>2013</b> , 162, 229-39	4.5	60
133	Effect of the Number of Prognostically Relevant Mutated Genes on Survival and Leukemia Progression in Primary Myelofibrosis. <i>Blood</i> , <b>2013</b> , 122, 104-104	2.2	3

132	Splanchnic Vein Thrombosis Associated With Myeloproliferative Neoplasms. A Study Of The IWG-MRT In 475 Subjects. <i>Blood</i> , <b>2013</b> , 122, 1582-1582	2.2	1
131	CML Patients In Clinical Trials Represent Fairly Well The General Population Of CML Patients: A Comparative Analysis Of 5803 Patients From The EUTOS Registry. <i>Blood</i> , <b>2013</b> , 122, 2735-2735	2.2	1
130	Phase 3 Study Of Pomalidomide In Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis With RBC-Transfusion-Dependence. <i>Blood</i> , <b>2013</b> , 122, 394-394	2.2	13
129	Impact Of Ruxolitinib On The Natural History Of Patients With Primary Myelofibrosis: A Retrospective Comparison Of The DIPSS and The Comfort-2 Cohorts. <i>Blood</i> , <b>2013</b> , 122, 4066-4066	2.2	1
128	Myeloproliferative (MPN) Symptom Burden Response Thresholds: Assessment Of MPN-SAF TSS Quartiles As Potential Markers Of Symptom Response. <i>Blood</i> , <b>2013</b> , 122, 4067-4067	2.2	6
127	Cerebral Vein Thrombosis In Patients With Myeloproliferative Neoplasms. <i>Blood</i> , <b>2013</b> , 122, 4068-4068	2.2	1
126	The Relationship Between Cytokine Levels and Symptoms in Patients (Pts) With Myelofibrosis (MF) From COMFORT-II, a Phase 3 Study of Ruxolitinib (RUX) Vs Best Available Therapy (BAT). <i>Blood</i> , <b>2013</b> , 122, 4070-4070	2.2	14
125	Insomnia, Quality Of Life and MPN Symptom Burden: An Analysis By The MPN Quality Of Life International Study Group (MPN-QOL ISG). <i>Blood</i> , <b>2013</b> , 122, 4087-4087	2.2	7
124	Sexuality Challenges, Intimacy, and MPN Symptom Burden: An Analysis By The MPN Quality Of Life International Study Group (MPN-QOL ISG). <i>Blood</i> , <b>2013</b> , 122, 4088-4088	2.2	6
123	BAALC-Associated Mir-3151 Is An Independent Prognostic Factor In Younger Patients With Intermediate-Risk Cytogenetic Acute Myeloid Leukemia. <i>Blood</i> , <b>2013</b> , 122, 2577-2577	2.2	
122	Overall Survival and Prognosis In Patients With First-Line Imatinib Treatment Under Consideration Of Death Due To Any Cause and Death Due To Chronic Myeloid Leukemia Only. <i>Blood</i> , <b>2013</b> , 122, 382-382 <sup>2</sup>		
121	Achievement and Maintenance Of Deeper Molecular Response By Switching To Nilotinib In Patients (pts) With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) With Residual Disease On Long-Term Imatinib: ENESTcmr 36-Month Follow-Up. <i>Blood</i> , <b>2013</b> , 122, 94-95	2.2	1
120	Prognostication in primary myelofibrosis. <i>Current Hematologic Malignancy Reports</i> , <b>2012</b> , 7, 43-9	4.4	17
119	JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. <i>New England Journal of Medicine</i> , <b>2012</b> , 366, 787-98	59.2	1232
118	Automated assessment of the neutrophil and platelet activation status in patients with essential thrombocythemia. <i>Platelets</i> , <b>2012</b> , 23, 336-43	3.6	11
117	Improving survival trends in primary myelofibrosis: an international study. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 2981-7	2.2	85
116	The Myelofibrosis Symptom Burden (MF-SB): An International Phenotypic Cluster Analysis of 329 Patients. <i>Blood</i> , <b>2012</b> , 120, 1731-1731	2.2	1
115	Switching to Nilotinib Is Associated with Continued Deeper Molecular Responses in CML-CP Patients with Minimal Residual Disease After 12 Years On Imatinib: Enestcmr 2-Year Follow-up Results. <i>Blood</i> , <b>2012</b> , 120, 694-694	2.2	2



114	Long-Term Safety, Efficacy, and Survival Findings From Comfort-II, a Phase 3 Study Comparing Ruxolitinib with Best Available Therapy (BAT) for the Treatment of Myelofibrosis (MF). <i>Blood</i> , <b>2012</b> , 120, 801-801	2.2	21
113	Reductions in JAK2 V617F Allele Burden with Ruxolitinib Treatment in Comfort-II, a Phase 3 Study Comparing the Safety and Efficacy of Ruxolitinib with Best Available Therapy (BAT). <i>Blood</i> , <b>2012</b> , 120, 802-802	2.2	7
112	Switch to nilotinib versus continued imatinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) with detectable BCR-ABL after 2 or more years on imatinib: ENESTcmr 12-month (mo) follow-up.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 6505-6505	2.2	1
111	Reductions in JAK2V617F allele burden with ruxolitinib treatment in COMFORT-II, a phase III study comparing the safety and efficacy of ruxolitinib to best available therapy (BAT).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 6514-6514	2.2	3
110	Association of cytokine levels and reductions in spleen size in COMFORT-II, a phase III study comparing ruxolitinib to best available therapy (BAT).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 6625-6625	2.2	4
109	Health-related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT-II study.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 6626-6626	2.2	4
108	JAKARTA: A phase III, multicenter, randomized, double-blind, placebo-controlled, three-arm study of SAR302503 in patients with intermediate-2 or high-risk primary myelofibrosis (MF), post-polycythemia vera (PV) MF, or post-essential thrombocythemia (ET) MF with splenomegaly.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, TPS6639-TPS6639	2.2	1
107	Patient Information and Examinations Needed Before Planning Therapy in the Myeloproliferative Neoplasms <b>2012</b> , 47-55		
106	Cytoreduction Plus Low-Dose Aspirin Versus Cytoreduction in Monotherapy As Primary Prophylaxis of Thrombosis in Patients with Essential Thrombocythemia.. <i>Blood</i> , <b>2012</b> , 120, 2828-2828	2.2	
105	Essential Thrombocythemia (ET) and Polycythemia Vera (PV) Symptom Burden: Phenotypic Cluster Analysis Among an International Sample of 1,141 ET and PV Patients. <i>Blood</i> , <b>2012</b> , 120, 1726-1726	2.2	
104	Comparison of the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Across Nine Linguistic Translations Among an International Sample of 1,851 Myeloproliferative Neoplasm (MPN) Patients.. <i>Blood</i> , <b>2012</b> , 120, 2852-2852	2.2	
103	Prediction of Overall Survival in 520 Patients with Primary Myelofibrosis: Outcome Update of the Dynamic International Prognostic Scoring System (DIPSS) Patient Cohort. <i>Blood</i> , <b>2012</b> , 120, 1729-1729	2.2	1
102	Advances in the understanding and management of primary myelofibrosis. <i>Current Opinion in Oncology</i> , <b>2011</b> , 23, 665-71	4.2	14
101	EZH2 mutational status predicts poor survival in myelofibrosis. <i>Blood</i> , <b>2011</b> , 118, 5227-34	2.2	204
100	Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 761-70	2.2	589
99	Practical management of patients with chronic myeloid leukemia. <i>Cancer</i> , <b>2011</b> , 117, 4343-54	6.4	18
98	DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 392-7	2.2	677
97	Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia. <i>Leukemia Research</i> , <b>2011</b> , 35, 1014-9	2.7	44

96	Management of essential thrombocythemia. <i>Hematology American Society of Hematology Education Program</i> , <b>2011</b> , 2011, 215-21	3.1	33
95	The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Derived Total Symptom Score (TSS): An International Trial of 1433 Patients with Myeloproliferative Neoplasms (MPNs),. <i>Blood</i> , <b>2011</b> , 118, 3839-3839	2.2	4
94	Prognostic Factors in Classic Myeloproliferative Neoplasms <b>2011</b> , 85-96		
93	Outcome of Patients with Chronic Myeloid Leukemia After Allogeneic Stem Cell Transplantation in Europe; Data From the EUTOS for CML Registry. <i>Blood</i> , <b>2011</b> , 118, 1688-1688	2.2	
92	Leukemia Risk Models in Primary Myelofibrosis: An International Working Group Study,. <i>Blood</i> , <b>2011</b> , 118, 3833-3833	2.2	
91	Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. <i>Nature Genetics</i> , <b>2010</b> , 42, 722-6	36.3	897
90	Outcome of transplantation for myelofibrosis. <i>Biology of Blood and Marrow Transplantation</i> , <b>2010</b> , 16, 358-67	4.7	206
89	Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. <i>Blood</i> , <b>2010</b> , 116, 2857-8	2.2	133
88	A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). <i>Blood</i> , <b>2010</b> , 115, 1703-8	2.2	645
87	Thrombosis in primary myelofibrosis: incidence and risk factors. <i>Blood</i> , <b>2010</b> , 115, 778-82	2.2	175
86	Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis--prognostic relevance is independent of IPSS or karyotype. <i>American Journal of Hematology</i> , <b>2010</b> , 85, 14-7	7.1	30
85	Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group. <i>Haematologica</i> , <b>2010</b> , 95, 1317-24	6.6	41
84	Response: Capturing variables with prognostic relevance in development of a new scoring system for primary myelofibrosis. <i>Blood</i> , <b>2010</b> , 115, 745-746	2.2	
83	Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients. <i>Annals of Hematology</i> , <b>2010</b> , 89, 1233-7	3	114
82	Association Between EZH2 and Other Acquired Mutations In Myelofibrosis and Myelodysplastic/Myeloproliferative Neoplasms. <i>Blood</i> , <b>2010</b> , 116, 625-625	2.2	
81	DIPSS-Plus: A Refined Dynamic International Prognostic Scoring System (DIPSS) for Primary Myelofibrosis That Incorporates Karyotype, Platelet Count and Transfusion Status. <i>Blood</i> , <b>2010</b> , 116, 4104-4104	2.2	1
80	Blood cell activation in myeloproliferative neoplasms. <i>Haematologica</i> , <b>2009</b> , 94, 1484-8	6.6	27
79	Pomalidomide is active in the treatment of anemia associated with myelofibrosis. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 4563-9	2.2	188

78	Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden. <i>American Journal of Hematology</i> , <b>2009</b> , 84, 102-8	7.1	94
77	Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 6041-51	2.2	1019
76	New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. <i>Blood</i> , <b>2009</b> , 113, 2895-901	2.2	905
75	Pomalidomide Therapy in Myelofibrosis: 2-Year Follow-up of a Randomized Phase 2 Study.. <i>Blood</i> , <b>2009</b> , 114, 1904-1904	2.2	1
74	Thrombosis in Primary Myelofibrosis: Incidence and Risk Factors.. <i>Blood</i> , <b>2009</b> , 114, 2915-2915	2.2	1
73	Transfusion Need at Diagnosis or Its Development During the First Year of Diagnosis in Primary Myelofibrosis: Effect On Survival and Correlation with JAK2 and TET2 Mutational Status.. <i>Blood</i> , <b>2009</b> , 114, 1909-1909	2.2	
72	A Dynamic Prognostic Model to Predict Survival in Primary Myelofibrosis: a Study of the International Working Group for Myeloproliferative Neoplasm Research and Treatment (IWG-MRT).. <i>Blood</i> , <b>2009</b> , 114, 3891-3891	2.2	
71	Platelet Antiaggregant Therapy Prevents Venous Thrombosis in Patients with JAK2 V617F Positive Essential Thrombocythemia without Indication of Cytoreductive Treatment.. <i>Blood</i> , <b>2009</b> , 114, 3906-3906 <sup>2,2</sup>	2.2	
70	Early Optimization of Imatinib Therapy in Patients Newly Diagnosed with Chronic-Phase Chronic Myeloid Leukemia (CP-CML). A Study of the Spanish PETHEMA Group.. <i>Blood</i> , <b>2009</b> , 114, 1113-1113	2.2	
69	A multivariate analysis of prognostic factors in chronic myelomonocytic leukaemia according to the FAB criteria. <i>British Journal of Haematology</i> , <b>2008</b> , 65, 307-311	4.5	
68	Conventional and New Treatment Modalities in Myelofibrosis and the Current Role of Transplantation. <i>Clinical Leukemia</i> , <b>2008</b> , 2, 39-45		
67	Increased platelet, leukocyte, and coagulation activation in primary myelofibrosis. <i>Annals of Hematology</i> , <b>2008</b> , 87, 269-76	3	36
66	A New Prognostic Scoring System for Primary Myelofibrosis Based on a Study of the International Working Group for Myelofibrosis Research and Treatment. <i>Blood</i> , <b>2008</b> , 112, 657-657	2.2	4
65	Pomalidomide Therapy in Anemic Patients with Myelofibrosis: Results from a Phase-2 Randomized Multicenter Study. <i>Blood</i> , <b>2008</b> , 112, 663-663	2.2	3
64	Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). <i>Leukemia Research</i> , <b>2007</b> , 31, 737-40	2.7	237
63	Myelofibrosis: biology and treatment options. <i>European Journal of Haematology</i> , <b>2007</b> , 79, 13-7	3.8	7
62	Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. <i>Blood</i> , <b>2007</b> , 109, 2303-9	2.2	498
61	Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. <i>Blood</i> , <b>2007</b> , 110, 3540-6	2.2	602

60	Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. <i>Blood</i> , <b>2007</b> , 110, 1092-7	2.2	715
59	New and old treatment modalities in primary myelofibrosis. <i>Cancer Journal (Sudbury, Mass)</i> , <b>2007</b> , 13, 377-83	2.2	49
58	JAK2 Mutations at Exon 12 and 14 in Polycythemia Vera and Idiopathic Erythrocytosis: Incidence and Correlation with Clinical Characteristics.. <i>Blood</i> , <b>2007</b> , 110, 2532-2532	2.2	
57	Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. <i>New England Journal of Medicine</i> , <b>2006</b> , 355, 2408-17	59.2	2811
56	Myelofibrosis with myeloid metaplasia: disease overview and non-transplant treatment options. <i>Best Practice and Research in Clinical Haematology</i> , <b>2006</b> , 19, 495-517	4.2	25
55	Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. <i>Blood</i> , <b>2006</b> , 108, 1809-20	2.2	998
54	International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). <i>Blood</i> , <b>2006</b> , 108, 1497-503	2.2	287
53	Darbepoetin-alpha for the anaemia of myelofibrosis with myeloid metaplasia. <i>British Journal of Haematology</i> , <b>2006</b> , 134, 184-6	4.5	63
52	Role of JAK 2 Mutation Detection in Budd-Chiari Syndrome (BCS) and Portal Vein Thrombosis (PVT) Associated to MPD.. <i>Blood</i> , <b>2006</b> , 108, 377-377	2.2	6
51	Tissue Factor and Soluble Markers of Platelet and Endothelial Activation in Essential Thrombocythemia: Relationship with Thrombosis and JAK2 V617F Mutation Status.. <i>Blood</i> , <b>2006</b> , 108, 2707-2707	2.2	
50	Essential Thrombocythemia in Young Individuals: Frequency and Risk Factors for Vascular Events and Evolution to Myelofibrosis in 126 Patients.. <i>Blood</i> , <b>2006</b> , 108, 3598-3598	2.2	
49	Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. <i>Haematologica</i> , <b>2006</b> , 91, 169-75	6.6	173
48	Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET). <i>Blood</i> , <b>2005</b> , 106, 2849-53	2.2	65
47	Modern management of myelofibrosis. <i>British Journal of Haematology</i> , <b>2005</b> , 128, 583-92	4.5	37
46	Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients. <i>British Journal of Haematology</i> , <b>2005</b> , 129, 771-5	4.5	112
45	Myelofibrosis with myeloid metaplasia: diagnosis, prognostic factors, and staging. <i>Seminars in Oncology</i> , <b>2005</b> , 32, 395-402	5.5	19
44	Survivin expression in the progression of chronic myeloid leukemia: a sequential study in 16 patients. <i>Leukemia and Lymphoma</i> , <b>2005</b> , 46, 717-22	1.9	25
43	Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature. <i>British Journal of Haematology</i> , <b>2004</b> , 127, 399-403	4.5	111

42	Increased CD11b neutrophil expression in Budd-Chiari syndrome or portal vein thrombosis secondary to polycythaemia vera. <i>British Journal of Haematology</i> , <b>2004</b> , 124, 329-35	4.5	19
41	Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. <i>New England Journal of Medicine</i> , <b>2003</b> , 348, 994-1004	59.2	2797
40	Genomic p16 abnormalities in the progression of chronic myeloid leukemia into blast crisis: a sequential study in 42 patients. <i>Experimental Hematology</i> , <b>2003</b> , 31, 204-10	3.1	35
39	Imatinib mesylate (STI571) treatment in patients with chronic-phase chronic myelogenous leukaemia previously submitted to autologous stem cell transplantation. <i>British Journal of Haematology</i> , <b>2003</b> , 120, 500-4	4.5	5
38	Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients. <i>Haematologica</i> , <b>2003</b> , 88, 1117-22	6.6	22
37	Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients. <i>British Journal of Haematology</i> , <b>2002</b> , 118, 786-90	4.5	111
36	Myelofibrosis with myeloid metaplasia in adult individuals 30 years old or younger: presenting features, evolution and survival. <i>European Journal of Haematology</i> , <b>2001</b> , 66, 324-7	3.8	19
35	Hypercalcemia as the presenting feature of t-cell lymphoid blast crisis of ph-positive chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , <b>2001</b> , 41, 203-6	1.9	9
34	Deoxycoformycin in the treatment of patients with hairy cell leukemia: results of a Spanish collaborative study of 80 patients. <i>Cancer</i> , <b>2000</b> , 88, 352-7	6.4	51
33	Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced hodgkin disease <b>2000</b> , 88, 2142-2148		11
32	Assessment of peripheral blood lymphocyte subsets in idiopathic myelofibrosis. <i>European Journal of Haematology</i> , <b>2000</b> , 65, 104-8	3.8	25
31	Blast crisis of Ph-positive chronic myeloid leukemia with isochromosome 17q: report of 12 cases and review of the literature. <i>Leukemia and Lymphoma</i> , <b>2000</b> , 38, 83-90	1.9	20
30	Non-Hodgkin's lymphoma following untreated essential thrombocythemia. <i>Leukemia and Lymphoma</i> , <b>2000</b> , 36, 421-3	1.9	6
29	The changing profile of idiopathic myelofibrosis: a comparison of the presenting features of patients diagnosed in two different decades. <i>European Journal of Haematology</i> , <b>1998</b> , 60, 101-5	3.8	21
28	Risk of relapse and clinico-pathological features in 103 patients with diffuse large-cell lymphoma in complete response after first-line treatment. <i>European Journal of Haematology</i> , <b>1998</b> , 61, 59-64	3.8	10
27	'Lymphoid' blast crisis of chronic myeloid leukaemia is associated with distinct clinicohaematological features. <i>British Journal of Haematology</i> , <b>1998</b> , 100, 123-8	4.5	67
26	Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups. <i>British Journal of Haematology</i> , <b>1998</b> , 102, 684-90	4.5	138
25	Non-Hodgkin's lymphoma associated with Gaucher's disease. <i>Leukemia and Lymphoma</i> , <b>1998</b> , 31, 609-12	1.9	20



24	Identification of 'short-lived' and 'long-lived' patients at presentation of idiopathic myelofibrosis. <i>British Journal of Haematology</i> , <b>1997</b> , 97, 635-40	4.5	143
23	Successful autografting in chronic myelogenous leukaemia using Philadelphia negative blood progenitor cells mobilized with rHuG-CSF alone in a patient responding to alpha-interferon. <i>British Journal of Haematology</i> , <b>1997</b> , 96, 421-3	4.5	8
22	An assessment of the clinicohematological criteria for the accelerated phase of chronic myeloid leukemia. <i>European Journal of Haematology</i> , <b>1996</b> , 57, 286-91	3.8	19
21	Hypercalcemia in a patient with chronic lymphocytic leukemia evolving into Richter's syndrome. <i>Leukemia and Lymphoma</i> , <b>1996</b> , 21, 521-3	1.9	12
20	Multiple myeloma following essential thrombocythemia. <i>Leukemia and Lymphoma</i> , <b>1995</b> , 20, 177-9	1.9	8
19	Long-term survivors in chronic granulocytic leukaemia: a study by the International CGL Prognosis Study Group. Italian Cooperative CML Study Group. <i>British Journal of Haematology</i> , <b>1994</b> , 87, 293-300	4.5	24
18	Impact of response to treatment on survival in multiple myeloma: results in a series of 243 patients. <i>British Journal of Haematology</i> , <b>1994</b> , 88, 117-21	4.5	47
17	Prognosis of chronic myeloid leukemia: studies from the Barcelona Group. <i>Leukemia and Lymphoma</i> , <b>1993</b> , 11 Suppl 1, 63-6	1.9	34
16	The value of detecting surface and cytoplasmic antigens in acute myeloid leukaemia. <i>British Journal of Haematology</i> , <b>1992</b> , 81, 178-83	4.5	30
15	Malignant transformation and life expectancy in monoclonal gammopathy of undetermined significance. <i>British Journal of Haematology</i> , <b>1992</b> , 81, 391-4	4.5	123
14	Assessment of iron stores in hospitalized patients. <i>American Journal of Clinical Pathology</i> , <b>1991</b> , 95, 105-6.9		
13	Liver dysfunction following splenectomy in idiopathic myelofibrosis: a study of 10 patients. <i>Acta Haematologica</i> , <b>1991</b> , 85, 184-8	2.7	49
12	Bone marrow histopathology in primary myelofibrosis: clinical and haematologic correlations and prognostic evaluation. <i>European Journal of Haematology</i> , <b>1990</b> , 44, 95-9	3.8	14
11	A study of prognostic factors in blast crisis of Philadelphia chromosome-positive chronic myelogenous leukaemia. <i>British Journal of Haematology</i> , <b>1990</b> , 76, 27-32	4.5	38
10	Scleroderma Associated with Idiopathic Myelofibrosis. <i>Leukemia and Lymphoma</i> , <b>1990</b> , 1, 153-5	1.9	4
9	Acute transformation of chronic myelomonocytic leukaemia: a multivariate study of predictive factors. <i>European Journal of Haematology</i> , <b>1989</b> , 42, 284-8	3.8	6
8	Is the histological classification of chronic granulocytic leukaemia justified from the clinical point of view?. <i>European Journal of Haematology</i> , <b>1989</b> , 42, 150-4	3.8	13
7	A new prognostic system for multiple myeloma based on easily available parameters. <i>British Journal of Haematology</i> , <b>1989</b> , 72, 507-11	4.5	31



6	Bone marrow lymphoid nodules in myeloproliferative disorders: association with the nonmyelosclerotic phases of idiopathic myelofibrosis and immunological significance. <i>British Journal of Haematology</i> , <b>1988</b> , 70, 279-82	4.5	24
5	Non-Hodgkin's lymphoma of unfavourable histology: a multivariate analysis of factors predicting the response to CHOP. <i>Hematological Oncology</i> , <b>1987</b> , 5, 203-11	1.3	2
4	Early T-cell features in blast crisis of Ph1-positive chronic myeloid leukaemia. <i>Scandinavian Journal of Haematology</i> , <b>1985</b> , 35, 71-6		8
3	Iron stores in chronic granulocytic leukaemia at presentation. <i>Scandinavian Journal of Haematology</i> , <b>1984</b> , 32, 469-74		10
2	Systemic lupus erythematosus and amyloidosis. <i>Arthritis and Rheumatism</i> , <b>1979</b> , 22, 554-6		25
1	Accurately assessing risk in your myeloproliferative neoplasm patient37-44		